PhRMA Says Fed. Circ. Botched Patent Term Extension Ruling
The Pharmaceutical Research and Manufacturers of America is urging the full Federal Circuit to reverse a panel decision tied to Biogen's blockbuster multiple sclerosis drug Tecfidera, warning that the panel's ruling...To view the full article, register now.
Already a subscriber? Click here to view full article